Publications

Clinical Research

• Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN-DU Cohort. Jonge JB, de Roock S, Schonenberg-Meinema D, van den Berg JM, Marshall DA, Vastert SJ, Yeung RSM, Swart JF, Benseler SM; UCAN CAN‐DU and UCAN CURE consortia. Effect of Time to Start of Biologic Therapy on Treatment Response in Childhood Arthritis: Results From the UCAN CAN-DU Cohort. Arthritis Rheumatol. 2026 Mar;78(3):743-751. doi: 10.1002/art.43401. Epub 2026 Jan 16. PMID: 40977426; PMCID: PMC12991923.

Immunobiology

• Interleukin-1–mediated hyperinflammation in XIAP deficiency is associated with defective autophagy. Dissanayake D, Firouzabady A, Massumi M, de Paz Linares GA, Marshall C, Freeman SA, Laxer RM, Yeung RSM

Health Economics & Patient Partnerships

• Uncovering the hidden socioeconomic impact of juvenile idiopathic arthritis and paving the way for other rare childhood diseases: an international, cross-disciplinary, patient-centered approach (PAVE Consortium). Marshall, D. A., Gerber, B., Currie, G. R., Antón, J., De Somer, L., Dey, M., Egert, T., Egert, Y., Henan, L., Klotsche, J., Mifsut, L. M., Minden, K., Normand, C., Porte, D., Saurenmann, R. K., Swart, J. F., Uziel, Y., Wilson, J., Wouters, C., Ziv, A., Benseler, S.M., on behalf of the PAVE Consortium (2024). Pediatric rheumatology online journal, 22(1), 74.
• Transitions from Pediatric to Adult Rheumatology Care for Juvenile Idiopathic Arthritis: A Patient Led Qualitative Study Currie GR, Harris M, McClinton L, Trehan N, Van Dusen A, Shariff M, Kuzmyn T, Marshall DA. Transitions from pediatric to adult rheumatology care for juvenile idiopathic arthritis: a patient led qualitative study. BMC Rheumatol. 2022 Nov 14;6(1):85. doi: 10.1186/s41927-022-00316-5. PMID: 36376987; PMCID: PMC9664794.
• Validation of the EQ-5D-Y-5L Parent-Proxy Version among Children with Juvenile Idiopathic Arthritis.Ohinmaa A, Wen J, Currie GR, Benseler SM, Swart JF, Vastert SJ, Yeung RSM, Marshall DA. Validation of the EQ-5D-Y-5L parent-proxy version among children with juvenile idiopathic arthritis. Qual Life Res. 2024 Oct;33(10):2677-2691. doi: 10.1007/s11136-024-03682-4. Epub 2024 Aug 14. PMID: 39141175; PMCID: PMC11452410.
• Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis. Florax AA, Doeleman MJH, de Roock S, van der Linden N, Schatorjé E, Currie G, Marshall DA, Jzerman MJI, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat NM, Swart JF, Kip MMA; for UCAN-CAN DU and UCAN CURE Consortia. Quantifying hospital-associated costs, and accompanying travel costs and productivity losses, before and after withdrawing TNF-α inhibitors in juvenile idiopathic arthritis. Rheumatology (Oxford). 2024 Sep 1;63(SI2):SI143-SI151. doi: 10.1093/rheumatology/kead688. Erratum in: Rheumatology (Oxford). 2025 Oct 1;64(10):5563. doi: 10.1093/rheumatology/keaf405. PMID: 38123516; PMCID: PMC11381678.
• Managing juvenile idiopathic arthritis within the context of their life: What we learnt from children and youth living with juvenile idiopathic arthritis and their parents. Currie GR*, Kennedy BL*, Benseler SM, Yeung RSM, Swart JF, Vastert SJ, Wulffraat NM, Kip MMA, MacKean G, Marshall DA. Musculoskeletal Care. 2023 Dec;21(4):1248–60.
• What matters most to pediatric rheumatologists in deciding whether to discontinue biologics in a child with juvenile idiopathic arthritis? A best-worst scaling survey. Currie GR, Groothuis-Oudshoorn CGM, Twilt M, Kip MMA, IJzerman MJ, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung R, Marshall DA. Clin Rheumatol. 2023 Aug;42(8):2173–80.
• Withdrawing biologics in non-systemic JIA: what matters to pediatric rheumatologists? Van Til JA, Kip MMA, Schatorjé EJH, Currie G, Twilt M, Benseler SM, Swart JF, Vastert SJ, Wulfraat N, Yeung RSM, Groothius-Oudshoorn CGM, Warta S, *Marshall DM, *Ijzerman MJ and on behalf of the UCAN CAN-DU, UCAN CURE consortia. Pediatr Rheumatol. 2023 Jul 11;21(1):69.
• Evaluating key performance indicators of the process of care in juvenile idiopathic arthritis. Cooper SM, Currie GR, Kromm S, Twilt M, Marshall DA. Pediatr Rheumatol. 2023 Apr 21;21(1):37.
• Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis. Kip MMA, De Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, Rae S M Yeung, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Rheumatology. 2023 Feb 23;62(SI2):SI170–80.
• Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study. Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Marshall DA. Pediatr Rheumatol. 2022 Dec;20(1):25.
• Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis. Grazziotin LR, Currie G, Twilt M, IJzerman MJ, Kip MMA, Koffijberg H, Bonsel G, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Armbrust W, Merlijn van den Berg J, Marshall DA. Pediatr Rheumatol. 2022 Dec;20(1):51.
• Costs of Hospital-associated Care for Patients With Juvenile Idiopathic Arthritis in the Dutch Health Care System. Kip MMA, De Roock S, Van Den Berg I, Currie G, Marshall DA, Grazziotin LR, Twilt M, Yeung RSM, Benseler SM, Vastert SJ, Wulffraat N, Swart JF, IJzerman MJ. Arthritis Care & Research. 2022 Oct;74(10):1585–92.
• Perspectives of Pediatric Rheumatologists on Initiating and Tapering Biologics in Patients with Juvenile Idiopathic Arthritis: A Formative Qualitative Study. Currie GR, Pham T, Twilt M, IJzerman MJ, Hull PM, Kip MMA, Benseler S, Hazlewood GS, Yeung R, Wulffraat N, Swart JF, Vastert SJ, Marshall DA. Patient. 2022 Sep;15(5):599–609.
• Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system. Kip MMA, De Roock S, Currie G, Marshall DA, Grazziotin LR, Twilt M, Yeung RSM, Benseler SM, Schreijer MA, Vastert SJ, Wulffraat N, van Royen-Kerkhof A, Swart JF, IJzerman MJ. Expert Review of Pharmacoeconomics & Outcomes Research. 2021 Sep 3;21(5):975–84.
• Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Bastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, Marshall DA. Rheumatol Ther. 2021 Sep;8(3):1303–22.
• A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. Barber CEH, Twilt M, Pham T, Currie GR, Benseler S, Yeung RSM, Batthish M, Blanchette N, Guzman J, Lang B, LeBlanc C, Levy DM, O’Brin C, Schmeling H, Soon G, Spiegel L, Whitney K, Marshall DA. Arthritis Res Ther. 2020 Dec;22(1):53.
• Health State Utility Values in Juvenile Idiopathic Arthritis: What is the Evidence? Grazziotin LR, Currie G, Kip MMA, IJzerman MJ, Twilt M, Lee R, Marshall DM. PharmacoEconomics. 2020 Sep;38(9):913–26.
• Seeking the state of the art in standardized measurement of health care resource use and costs in juvenile idiopathic arthritis: a scoping review. Kip MMA, Currie G, Marshall DA, Grazziotin Lago L, Twilt M, Vastert SJ, Swart JF, Wulffraat N, Yeung RSM, Benseler SM, Ijzerman M. Pediatr Rheumatol. 2019 Dec;17(1):20.

Data Sharing

• A Roadmap for Navigating Child Health Research Data Sharing across Canada and beyond – Building on UCAN CAN-DU. Gerber, B., Currie, G. R., Mosoiu, A., Bernier, A., Bernier, F. P., Boycott, K. M., Fiebelkorn, G., Hens, K., Knoppers, B. M., LeBlanc, C., Scherer, S. W., Shaw, D., Viney, C., Virtanen, C., Benseler, S. M., Yeung, R. S. M., & Marshall, D. A. (2025). A roadmap for navigating child health research data sharing across Canada and beyond – building on UCAN CAN-DU. Pediatric Rheumatology, 23(1), 89. https://doi.org/10.1186/s12969-025-01139-7